Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on April 2, 2007

Hypertension. 2007
Published online before print April 2, 2007, doi: 10.1161/HYPERTENSIONAHA.107.087890
A more recent version of this article appeared on June 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
49/6/1385    most recent
HYPERTENSIONAHA.107.087890v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mehta, S. K.
Right arrow Articles by Drazner, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mehta, S. K.
Right arrow Articles by Drazner, M. H.
Related Collections
Right arrow Risk Factors
Right arrow Hypertrophy
Right arrow Myocardial cardiomyopathy disease
Right arrow Epidemiology

Submitted on January 22, 2007
Revised on February 5, 2007

Left Ventricular Hypertrophy, Subclinical Atherosclerosis, and Inflammation

Sameer K. Mehta; J. Eduardo Rame; Amit Khera; Sabina A. Murphy; Russell M. Canham; Ronald M. Peshock; James A. de Lemos; and Mark H. Drazner*

From the Donald W. Reynolds Cardiovascular Clinical Research Center and Divisions of Cardiology (S.K.M., J.E.R., A.K., R.M.C., R.M.P., J.A.d.L., M.H.D.), Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas; and the TIMI Study Group (S.A.M.), Boston, Mass.

* To whom correspondence should be addressed. E-mail: Mark.Drazner{at}UTSouthwestern.edu.

Abstract--To elucidate mechanisms by which left ventricular (LV) hypertrophy (LVH) increases the risk of atherosclerotic heart disease, we sought to determine whether LVH is independently associated with coronary artery calcium (CAC) and serum C-reactive protein (CRP) levels in the general population. The Dallas Heart Study is a population-based sample in which 2633 individuals underwent cardiac MRI to measure LV structure, electron beam CT to measure CAC, and measurement of plasma CRP. We used univariate and multivariable analyses to determine whether LV mass and markers of concentric LV hypertrophy or dilation were associated with CAC and CRP. Increasing quartiles of LV mass indexed to fat-free mass, LV wall thickness, and concentricity, but not LV volume, were associated with CAC in both men and women (P<0.001). After adjustment for traditional cardiovascular risk factors and statin use, LV wall thickness and concentricity remained associated with CAC in linear regression (P<0.001 for each). These associations were particularly robust in blacks. LV wall thickness and concentricity were also associated with elevated CRP levels (P=0.001 for both) in gender-stratified univariate analyses, although these associations did not persist in multivariable analysis. In conclusion, concentric LVH is an independent risk factor for subclinical atherosclerosis. LVH is also associated with an inflammatory state as reflected in elevated CRP levels, although this relationship appears to be mediated by comorbid conditions. These data likely explain in part why individuals with LVH are at increased risk for myocardial infarction.


Key words: left ventricular hypertrophy • atherosclerosis • inflammation • myocardial infarction • coronary artery disease




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
E. Mousseaux
Obesity and cardiovascular disease: how can cardiac magnetic resonance help?
J. Am. Coll. Cardiol., August 18, 2009; 54(8): 727 - 729.
[Full Text] [PDF]


Home page
Eur Heart JHome page
S. S. Kushwaha, E. Raichlin, Y. Sheinin, W. K. Kremers, K. Chandrasekaran, G. J. Brunn, and J. L. Platt
Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients
Eur. Heart J., November 2, 2008; 29(22): 2742 - 2750.
[Abstract] [Full Text] [PDF]